Teva, Eli Lilly Have Migraine Treatments in Trial Phases



Migraine segment opportunities

Currently in its Phase 3 clinical trials, Teva Pharmaceutical’s (TEVA) investigational drug, TEV-48125, is being explored as a preventive therapy for chronic and episodic migraine, as well as for cluster headaches. To learn more about the company’s efforts in this area, please read Teva: Developments in the Migraine Prevention Segment.

On June 17, 2015, Eli Lilly (LLY) also announced that LY2951742 (galcanezumab), an investigational drug, met the primary endpoints in the Phase 2b trial. This demonstrated its efficacy as a prevention therapy for episodic migraine.

If these investigational drugs can report positive results in their Phase 3 trials, it could boost the share prices of Teva Pharmaceutical, Eli Lilly’s, and the VanEck Vectors Pharmaceutical ETF (PPH). Teva Pharmaceutical makes up ~4.4% of PPH’s total portfolio holdings.

Article continues below advertisement

Galcanezumab migraine program

The above diagram shows results from Phase 2 clinical trials, where galcanezumab has demonstrated significant efficacy over a placebo as preventive therapy for episodic migraine, both in case of patients with a 50% and a 100% reduction in migraine headache days.

The investigational drug has also displayed limited safety reactions as compared to a placebo. Patients who were injected with galcanezumab witnessed a modest increase in injection site reactions as compared to the counterparts administered with a placebo.

Mode of administration

TEV-48125, Galcanezumab, and Amgen’s (AMGN) and Novartis’s (NVS) AMG 334 were administered as subcutaneous injections in the Phase 2 clinical trials, testing the efficacy of the investigational drugs for migraine prevention.

Alder BioPharmaceuticals’s migraine prevention drug, ALD403, was able to demonstrate strong efficacy in its Phase 2 trials. It also supports a quarterly dosing regimen across intravenous, subcutaneous, or intramuscular modes of delivery. With migraine patients preferring ease of use, the injectable or oral delivery options are expected to be preferred over the intravenous mode of delivery.


More From Market Realist